Home > Cluster Organisations > BioRN - Life Science Cluster Rhine-Neckar

BioRN - Life Science Cluster Rhine-Neckar

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Monday, 21 October, 1996
Number of staff in the management team of the cluster organisation : 
1-5
Cluster Excellence Label: 
Silver Label
Other Label: 
Leading-edge Cluster Competition Winner (Germany)
Membership to other networks/partnerships: 
NameWebsite
Health Axis Europe Alliance
Cluster Management Team: 
NameSurnamePositionEmailGender
Julia
Schaft
Cluster Manager
js@biorn.org
Female
Annalisa
Zuccotti
ECCP Responsible Person
az@biorn.org
Female
Friedemann
Loos
Project Manager
fl@biorn.org
Male
Birgit
Rogell
Project Manager
br@biorn.org
Languages spoken: 
English
German
Italian
Spanish
Sectoral and Industrial Focus
Sectoral Industries: 
Biopharmaceuticals
Technology fields: 
Cellular and Molecular Biology
Gene Expression, Proteome Research
S3 EU priority areas: 
Basic pharmaceutical products & pharmaceutical preparations
Biotechnology
Emerging industries: 
Bio-pharmaceuticals
Medical Devices
Areas of specialisation of the cluster not covered above: 
Personalised Medicine
Composition of the cluster
Total number of members: 
85
Number of SME members: 
50
Number of start-ups among SME members: 
10
Number of larger company members: 
15
Number of research organisations/universities/technology centres: 
10
Number of other ecosystem actors : 
5
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Organisation/Facility NameOrganisation/Facility TypeWebsite
Technology Park Heidelberg
Technology center
Heidelberg Start-up partners
Accelerator
Name and link of major players: 
Cluster Strategy
Mission/Objectives: 

BioRN is a bio-medical research and industry cluster dedicated to the development of the Rhine-Main-Neckar region into one of the world-leading life science cluster. The region counts on a rich startup ecosystem, international public and private investments and attracts top global talent.

As a strong network, BioRN promotes cooperation between companies, authorities and universities and works as facilitator between institutions performing basic or applied research, between global healthcare companies and SMEs or start-ups.

Within the scope to strength its visibility and role on national and international level, BioRN recently intensified the collaboration with the Ci3 cluster in Mainz. In terms of the use of clusters for the internationalization of companies, BioRN has founded, together with Leuven (Belgium), Maastricht (Netherlands) and Copenhagen (Denmark), an alliance for the enforcement of biomedical innovation in Europe, called the Health Axis Europe (https://www.health-axis.eu/).

Do you have a formalised strategy?: 
Yes
Do you have a specific strategy focus that addresses internationalisation ?: 
Yes
Services
Support services provided: 
Access to the European Internal market
Facilitation of collaboration between members
Trend-scouting (Ideas for innovative projects)
Support of technology transfer
Location promotion / attraction of Foreign Direct Investment
Details of support services: 

Stakeholder Alignment & Networking Initiatives to bridge the regional innovation stakeholders

  • Representation of innovation stakeholders in BioRN panels
  • Public relations – Promote news, activities and successes of all stakeholders
  • Monthly BioRN Lounges (networking event)
  • BioRN Annual Conference
  • Thematic workshops held for and by BioRN members
  • International network: Health Axis Europe

Promotion and Visibility Initiatives to promote the applied biosciences in the region

  • Lobbying for the life science region
  • Lobbying for new sources of project funding
  • Public relations –promote cluster and its members, including tall poppies
  • Attract High profile (international) events in the region

Translation Support

Leveraging the unique combination of global pharma and leading innovators in our network through HAEP (Health Axis Europe Partnering) – Pilot Phase

Leveraging the unique combination of global pharma and leading innovators in our network, by Accelerate academic research to the clinic – Conception Phase

Nurturing the regional startup ecosystem to create the next generation of powerhouse biotech companies by providing innovators with the space and resources to test, challenge, and nurture early stage ideas - Conception Phase

Startups and SMEs Support

  • Project Management
  • International Projects
  • Accelerators programs (European Health Catapult)
  • Identification of funding opportunities

 

Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries targeted by the cluster organisation: 
Belgium
Denmark
France
Netherlands
Norway
Our cluster organisation undertook the following trans-national activities to support our members: 
Participation at missions/events/study visits/fairs
Please explain: 

Health Axis Europe (HAE). The Health Axis Europe (HAE) is a strategic alliance between the biomedical clusters Leuven (Belgium), Heidelberg (Germany), Maastricht (Netherlands), and Copenhagen (Denmark) in order to cross-leverage innovation resources and thus jointly increase international competitiveness.

The biomedical clusters in Leuven, Heidelberg, Maastricht and Copenhagen share a common innovation culture, are comparable in strength and have complementary areas of expertise:

  • All four clusters are centered around internationally outstanding universities with excellent health sciences and a strong tradition in top education and research.
  • All four clusters have a substantial health industry base and are driven by strong key individuals that are personally committed to foster economic growth and entrepreneurship.
  • All four clusters are focused on complementary health technology areas covering medical electronics and nanotechnology (Leuven), personalized medicine and cancer research (Heidelberg), high-performance biomedical materials and Regenerative Medicine (Maastricht) as well as pharmacology and public health science (Copenhagen).

 

Objectives

The purpose of the Health Axis Europe initiative is to cross-leverage the innovation resources and thus jointly increase the international competitiveness of the clusters in Leuven, Heidelberg, Maastricht and Copenhagen.

  • Facilitate and coordinate EU-funded collaborative R&D projects (H2020, Horizon Europe, EIT Health IMI etc.)
  • Support of cross-border cooperation in the training and further education of talented persons
  • Nurture an international startup culture and attract cross-border investments (European Health Catapult)
  • Mediate international partnering between academia, SMEs and global healthcare companies (Health Axis Europe Partnering)
  • Facilitate scientific exchange in fast evolving visionary health research topics  (Health Axis Europe Visionary Seminars)

Health Axis Europe Partnering (HAEP) Project. The project aims to bundle the innovative strengths of science and industry and will provide a new tool for facilitated international knowledge exchange between academia and small and medium-sized enterprises on the one side and Global Healthcare Companies (GHCs) on the other. It effectively matches innovation seekers with innovators from a broad international network.

Which clusters do you collaborate with?: 
Biopeople (DK)
Oslo Cancer Cluster (NO)
Eurosanté (FR)
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject NameName & Description (Regional/National)
EIT KICs

BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to 700 million euros and a total project volume of more than 2 billion euros, this is one of the largest publicly funded initiatives in the health sector worldwide.

In September 2008, BioRN was honoured by the German Federal Ministry of Education and Research (BMBF) as a leading edge cluster "Cell-based & molecular medicine in the Rhine-Neckar metropolitan region" (Spitzencluster). Between 2009 and 2013, the associated funding of 40 million euros went into more than 40 R&D projects for which BioRN successfully carried out project management over the project period.

Another success of the BioRN cluster in 2015 was the winning of the BMBF competition for the internationalisation of top clusters. Since 2016, BioRN has been carrying out several BMBF-funded initiatives within this measure, which strengthen the internationalisation potential of SMEs and start-up companies in particular, but also of the region in general (https://www.bmbf.de/de/cluster-netzwerke-international-547.html). Since 2017, three international projects have been funded within the internationalisation initiative because they are in line with the internationalisation strategy developed by BioRN.

One of this projects is the Health Axis Europe Partnering (HAEP). The project aims to bundle the innovative strengths of science and industry and will provide a new tool for facilitated international knowledge exchange between academia and small and medium-sized enterprises on the one side and Global Healthcare Companies (GHCs) on the other. It effectively matches innovation seekers with innovators from a broad international network. In the BMBF funded validation phase (2018-2019) a concept of the new matching tool will be developed, tested and validated. The HAEP Team works closely with technology transfer offices and other innovation engines within the network.